Early effects of different cytostatic protocols for head and neck cancer on oncogene activation in animal experiments.
In vivo investigations on oncogenes and onco-suppressor genes may provide new findings on the potential carcinogenic effects of various cytostatic protocols inducing secondary tumours of the head and neck. Further surgeries are often necessary due to regional recurrence after the Cisplatin-supplemented BVM (Bleomycin, Vincristine, Methotrexate) protocol in the treatment of human head and neck tumours. Our earlier studies have illustrated the carcinogenic and mutagenic potential of Cisplatin. The effect of Cisplatin on the alteration of different onco- and suppressor genes has also been proven. Our present study aimed at investigating the early effects of the BVM and the CFu (Cisplatin, 5-Fluorouracil) protocols on early oncogene and tumour suppressor gene expressions in mice. Body weight equivalent amounts of cytostatics were administered intraperitoneally to 6- to 8-week-old, inbred, female CBA/Ca mice. Twenty-four, 48 and 72 hours after the treatment, RNA was isolated from the target organs and the quantitative expression of c-myc, Ha-ras and p53 genes were examined. The protocols caused detectable changes. A "short-term" in vivo test, the 24-hour examination of gene expression, is suitable for detecting early effects of carcinogen exposure. The alterations of gene expression, caused by the Cisplatin-containing protocol, draw attention to the probable role of Cisplatin in the development of regional recurrence and to the possibility of prevention.
Németh
A
A
Dept. of Public Health, Faculty of Medicine, University of Pécs, H-7643 Szigeti u. 12, Hungary. arpadnemeth@freemail.hu
Nadasi
E
E
Gyöngyi
Z
Z
Olasz
L
L
Nyarady
Z
Z
Ember
A
A
Kvarda
A
A
Bujdoso
L
L
Arany
I
I
Kiss
I
I
Csejtey
I
I
Ember
I
I
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D004195:Disease Models, Animal; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage; D051379:Mice; D008808:Mice, Inbred CBA; D013154:Spleen / Q000187:drug effects / Q000473:pathology; D014750:Vincristine / Q000008:administration & dosage
D001761:Bleomycin; D014750:Vincristine; D002945:Cisplatin; D008727:Methotrexate